Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Lentiviral vector-based in vivo CAR-T programs require a clear understanding of how candidate vectors perform in relevant immune-cell environments. Beyond transduction performance, our in vitro studies assess CAR expression across selected immune-cell populations, characterize the phenotype of CAR-expressing T cells, and evaluate antigen-dependent effector function.
We apply fit-for-purpose cellular and analytical methods to characterize lentiviral vector-mediated CAR expression and downstream immune-cell responses. Depending on study objectives, the assessment framework may integrate multiparameter flow cytometry, target-cell co-culture, cytotoxicity assays, cytokine and effector-response analysis, and molecular quantification.
Our preclinical CRO services generate integrated data on transduction, CAR expression, cellular phenotype, and functional activity. These data can support selection of study conditions and preparation for subsequent in vivo pharmacology, biodistribution, and safety evaluations.
This module assesses the ability of lentiviral vector candidates to mediate CAR expression in selected immune-cell systems.
Studies may be performed with peripheral blood mononuclear cells (PBMCs), enriched CD3+ T cells, CD4+ or CD8+ T-cell populations, or other project-relevant cell systems. Where constructs include reporter genes, reporter expression may be incorporated as a supporting transduction readout.
Assessment Endpoints
Applicable Methods
We select the CAR detection strategy based on construct design, reagent availability, and sample characteristics. For CAR constructs without a broadly applicable detection reagent, assay suitability can be evaluated before the main study.
This module characterizes the distribution of CAR expression or vector-associated signal across selected immune-cell subsets. It supports assessment of cell-population distribution patterns for lentiviral vector candidates in the selected in vitro immune-cell system.
The flow cytometry panel is configured according to the study objective, sample type, and relevant cell populations.
Cell Populations
Key Readouts
We interpret these results in the context of the tested vector, cell source, culture conditions, selected time points, and control design. The resulting dataset provides an in vitro view of cell-subset-associated CAR expression and complements downstream in vivo studies.
This module evaluates the phenotype of CAR-expressing T cells to characterize cellular status following lentiviral vector transduction. The analysis can provide data on viability, activation, differentiation-associated features, and selected dysfunction-associated markers.
Flow cytometry panels may be configured as focused characterization panels or expanded according to project objectives.
Core Phenotypic Endpoints
Optional Extended Endpoints
Phenotypic data can be integrated with CAR expression, target-cell killing, and cytokine-release results to provide a consolidated characterization of the tested CAR-expressing cell population.
This module evaluates the ability of CAR-expressing effector cells generated after lentiviral vector transduction to kill target cells under defined co-culture conditions.
We design cytotoxicity studies with antigen-positive target cells, antigen-negative or low-expression control cells, and relevant effector-cell comparators. This approach supports assessment of target-cell killing in relation to target-antigen expression and background activity.
Typical Study Elements
Key Readouts
Depending on target-cell characteristics, assay duration, and intended endpoints, cytotoxicity may be assessed using flow cytometry, fluorescenceor luminescence-based methods, cell counting, or real-time cell analysis.
This module assesses cytokine release and effector-function-associated responses following co-culture of CAR-expressing cells with target cells. These assays complement cytotoxicity assessments by characterizing cellular responses under antigen-stimulation conditions.
We configure the cytokine panel based on the target antigen, CAR signaling architecture, target-cell model, co-culture duration, and project requirements.
Commonly Assessed Analytes
Key Readouts
Cytokine and effector-function analysis can be performed using ELISA, multiplex cytokine platforms, flow cytometry, and other fit-for-purpose analytical approaches.
Core Technologies
Cell Systems
Relevant Preclinical Models
Assessment studies using PBMCs, enriched T-cell populations, and project-relevant target-cell systems.
Integrated Cellular and Functional Assessment
CAR expression, immune-cell subset distribution, T-cell phenotype, cytotoxicity, and cytokine response can be evaluated within a defined study framework.
Fit-for-Purpose Study Design
Assay panels and endpoints are configured according to the CAR construct, target antigen, vector candidates, and study objectives.
Clear, Decision-Supporting Deliverables
Data packages include defined study conditions, relevant controls, summarized results, and technical interpretation to support preclinical program decisions.
Define an in vitro assessment strategy for your lentiviral vector-based in vivo CAR-T program, including transduction, CAR expression, immune-cell profiling, and functional testing endpoints.
Copyright © 2026 Creative Biogene. All rights reserved.